TTM
$3.47B
YoY change
+57.8%
5Y CAGR
+48.9%
Peak year (2025)
$3.04B
Cumulative gross profit
$10.49B
Gross Profit history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $3.04B
Gross Profit growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: +57.8%
Gross Profit history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $3.04B | +57.8% | +$1.11B | ||
| 2024 | $1.92B | +26.8% | +$406.99M | ||
| 2023 | $1.52B | +74.8% | +$649.28M | ||
| 2022 | $868.60M | +23.4% | +$164.46M | ||
| 2021 | $704.14M | +69.8% | +$289.34M | ||
| 2020 | $414.80M | +113.1% | +$220.11M | ||
| 2019 | $194.69M | +166.3% | +$121.58M | ||
| 2018 | $73.11M | -4.5% | −$3.44M | ||
| 2017 | $76.55M | +62.3% | +$29.39M | ||
| 2016 | $47.16M | +14.8% | +$6.06M | ||
| 2015 | $41.10M | -18.7% | −$9.46M | ||
| 2014 | $50.56M | +7.2% | +$3.39M | ||
| 2013 | $47.17M | -29.3% | −$19.56M | ||
| 2012 | $66.72M | -19.4% | −$16.03M | ||
| 2011 | $82.76M | -17.3% | −$17.28M | ||
| 2010 | $100.04M | -0.5% | −$492.00K | ||
| 2009 | $100.53M | +4.5% | +$4.37M | ||
| 2008 | $96.16M | +88.9% | +$45.27M | ||
| 2007 | $50.90M | +89.0% | +$23.97M | ||
| 2006 | $26.93M | +371.1% | +$21.21M | ||
| 2005 | $5.72M | +33.6% | +$1.44M | ||
| 2004 | $4.28M | +2330.7% | +$4.10M | ||
| 2003 | $176.00K | — | +$176.00K | ||
| 2002 | $0.00 | — | — |
- 2025$3.04B+57.8%
- 2024$1.92B+26.8%
- 2023$1.52B+74.8%
- 2022$868.60M+23.4%
- 2021$704.14M+69.8%
- 2020$414.80M+113.1%
- 2019$194.69M+166.3%
- 2018$73.11M-4.5%
- 2017$76.55M+62.3%
- 2016$47.16M+14.8%
- 2015$41.10M-18.7%
- 2014$50.56M+7.2%
- 2013$47.17M-29.3%
- 2012$66.72M-19.4%
- 2011$82.76M-17.3%
- 2010$100.04M-0.5%
- 2009$100.53M+4.5%
- 2008$96.16M+88.9%
- 2007$50.90M+89.0%
- 2006$26.93M+371.1%
- 2005$5.72M+33.6%
- 2004$4.28M+2330.7%
- 2003$176.00K—
- 2002$0.00—
Gross Profit values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current gross profit (TTM) is $3.47B. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Alnylam Pharmaceuticals (ALNY) most recent annual gross profit stands at $3.04B (2025) – surged 57.8% year-over-year.
Alnylam Pharmaceuticals gross profit compound annual growth for the 2020–2025 (5 years) window is +48.9%, sustaining 7 straight years of year-over-year growth.
Across the available history, gross profit reached its high of $3.04B in 2025 and its low of $0.00 in 2002.
Alnylam Pharmaceuticals Gross Profit by Year
Alnylam Pharmaceuticals Gross Profit 2025: $3.04B
Alnylam Pharmaceuticals gross profit in 2025 was $3.04B, surged 57.8% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Gross Profit 2024: $1.92B
2024's gross profit for Alnylam Pharmaceuticals came in at $1.92B, grew 26.8% from 2023.
Alnylam Pharmaceuticals Gross Profit 2023: $1.52B
Alnylam Pharmaceuticals posted gross profit of $1.52B in 2023, surged 74.8% from 2022.
Alnylam Pharmaceuticals Gross Profit 2022: $868.60M
In 2022, Alnylam Pharmaceuticals reported gross profit of $868.60M, grew 23.4% from 2021.
Alnylam Pharmaceuticals Gross Profit 2021: $704.14M
Alnylam Pharmaceuticals gross profit in 2021 was $704.14M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Gross Profit
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation